GFPT1 and pancreatic neoplasm: Targeting tumor-intrinsic hexosamine biosynthesis by direct inhibition of GFPT1/2 by a small molecule glutamine analog (6-diazo-5-oxo-l-norleucine, DON) was recently shown to sensitize pancreatic cancer to anti-PD1 therapy and to result in tumor regression and prolonged survival13.